ArticleAlzheimer's research & therapy2025
Protein fingerprints of brain-derived extracellular vesicles predict types of tau pathology.
Article in Alzheimer's research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTauopathies are a heterogeneous group of neurodegenerative disorders characterized by the brain-regional aggregation of three-repeat (3R) or four-repeat (4R) tau isoforms. Current fluid and imaging biomarkers rarely discriminate these isoforms, hampering early, pathology‑specific diagnosis.
objectiveTo determine whether proteomic fingerprints of brain‑derived extracellular vesicles (BD‑EVs) isolated from the prefrontal cortex can (i) distinguish 3R from 4R tauopathies and (ii) mirror the histopathological burden of phosphorylated tau.
methodsBD‑EVs were purified from post‑mortem prefrontal cortex interstitial fluid of Pick’s disease (PiD; 3R), progressive supranuclear palsy (PSP; 4R), and control cases (CTRL). Nanoparticle tracking analysis quantified the concentration and size of vesicles. Label‑free LC–MS/MS profiled BD‑EV proteomes, followed by differential expression, gene set enrichment (GSEA), weighted gene co‑expression network analysis (WGCNA), and machine‑learning classification. AT8 immunohistochemistry quantified cortical tau pathology, enabling protein–pathology correlations.
resultsTau pathology did not alter overall BD‑EV yield but shifted vesicle size distribution in PiD (higher small/large EV ratio). Proteomic analysis identified two discriminant modules: an astrocyte-derived mitochondrial cluster enriched in PiD and a neuron-derived microtubule cluster depleted in PiD relative to PSP and control groups. Combined glial protein abundance (e.g., GFAP, AQP4, S100β, GLAST, ANXA1) classified PiD, PSP, and controls with perfect accuracy (F1 = 1.0). Several BD‑EV proteins—including CAMKV, TMEM30A, NMT1, AK1 (PiD‑specific), and CALB2 (PSP‑specific)—correlated strongly with regional AT8 burden (|ρ| ≥ 0.70, FDR < 0.05).
conclusionsBD‑EV proteomic fingerprints robustly differentiate 3R and 4R tauopathies and track disease severity, unveiling astrocytic mitochondrial proteins as candidate biomarkers. Overall, our results indicate that BD-EV profiling may complement existing approaches for distinguishing tau isoforms and, pending further validation, could ultimately be adapted for use in more accessible biofluids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.